This cholesterol pill may fight high risk of heart attack, stroke: Study

An international team of researchers found that a cholesterollowering drug may offer a more effective and convenient way to protect people at high risk of heart attack and strokeThe study led by researchers at Monash University in Australia tested a oncedaily oral medication called Obicetrapib and found it significantly lowered both LDL or bad cholesterol and lipoproteina Lpa two key contributors to cardiovascular diseaseThe findings marked an important step forward for patients who have struggled to reach their cholesterol targets with current therapies said study lead professor Stephen Nicholls Director of Monash Universitys Victorian Heart InstituteWe know that many people at high risk of heart attack or stroke dont get their cholesterol levels low enough even on the best available treatments Nicholls saidObicetrapib offers a promising new optionnot only did it lower LDL cholesterol by over 30 per cent but we also saw a reduction in Lpa which is much harder to treat and has been linked to increased heart disease risk he addedLDL cholesterol often referred to as bad cholesterol builds up in blood vessels and increases the risk of heart attack and strokeLipoproteina or Lpa is a lesserknown but inherited risk factor that can also accelerate artery damage and unlike LDL there are currently no widely approved treatments to lower itThe trial published in the New England Journal of Medicine included more than 2500 participants with established heart disease or genetic high cholesterol who were given either Obicetrapib or a placebo in addition to their regular cholesterol medicationsAfter 12 weeks those on Obicetrapib had dropped their LDL cholesterol by 326 per cent and Lpa by 335 per cent on average many achieved guidelinerecommended targets for the first timeObicetrapib was also well tolerated with a safety profile similar to earlier trialsThis could be a valuable tool in the fight against heart disease Professor Nicholls said Its convenient its effective and it may help close the gap for patients whove run out of optionsThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoeveratOptionskeyd0ddb8ef8f1a62a8cdd22fac27fc5ea7formatiframeheight90width728params